Next Article in Journal
The Heart Club: How Cyanotic Heart Disease Was Reframed
Next Article in Special Issue
Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome
Previous Article in Journal
Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
Open AccessReview

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina 45110, Greece
*
Author to whom correspondence should be addressed.
Diseases 2017, 5(4), 21; https://doi.org/10.3390/diseases5040021
Received: 14 September 2017 / Revised: 28 September 2017 / Accepted: 29 September 2017 / Published: 29 September 2017
Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipoprotein cholesterol (HDL) cholesterol levels and decrease low-density lipoprotein cholesterol (LDL) cholesterol concentration. However, three drugs of this class failed to show a decrease of cardiovascular events in high-risk patients. A new CETP inhibitor, anacetrapib, substantially increases HDL cholesterol and apolipoprotein (Apo) AI levels with a profound increase of large HDL2 particles, but also pre-β HDL particles, decreases LDL cholesterol levels mainly due to increased catabolism of LDL particles through LDL receptors, decreases lipoprotein a (Lp(a)) levels owing to a decreased Apo (a) production and, finally, decreases modestly triglyceride (TRG) levels due to increased lipolysis and increased receptor-mediated catabolism of TRG-rich particles. Interestingly, anacetrapib may be associated with a beneficial effect on carbohydrate homeostasis. Furthermore, the Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial showed that anacetrapib administration on top of statin treatment significantly reduces cardiovascular events in patients with atherosclerotic vascular disease without any significant increase of adverse events despite its long half-life. Thus, anacetrapib could be useful for the effective management of dyslipidemias in high-risk patients that do not attain their LDL cholesterol target or are statin intolerable, while its role in patients with increased Lp(a) levels remains to be established. View Full-Text
Keywords: anacetrapib; cholesteryl ester transfer protein; cardiovascular disease; apolipoprotein; diabetes anacetrapib; cholesteryl ester transfer protein; cardiovascular disease; apolipoprotein; diabetes
Show Figures

Figure 1

MDPI and ACS Style

Filippatos, T.D.; Kei, A.; Elisaf, M.S. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases 2017, 5, 21.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop